Innovative therapeutics

Investors/
Media

Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News
Oct 16, 2018

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company earned $15 million in milestone payments from Pfizer Inc. These milestone payments were triggered by the U.S. Food and...

Oct 11, 2018

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the twenty-five high school students from across the U.S. who will participate in 'Hemophilia: The Musical,' a first-of-its-kind...

Oct 11, 2018

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Forbes' named the company to its list, Global 2000: World's Best Employers. It is ranked within the top 300 out of a total of 2000...


Stock Quote
NASDAQBMRN
BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information